All Updates

All Updates

icon
Filter
Product updates
iRhythm wearable heart monitor increases AFib diagnoses by 52%
Preventive Healthcare
Sep 2, 2024
This week:
Partnerships
Microsoft and BlackRock partner to launch USD 30 billion AI data center investment fund
Machine Learning Infrastructure
Today
Funding
Limitless Labs raises USD 3 million in pre-seed funding to develop prediction market
Web3 Ecosystem
Today
Product updates
Google Cloud launches Blockchain RPC service for Web3 developers
Web3 Ecosystem
Today
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Machine Learning Infrastructure
Today
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Generative AI Infrastructure
Today
Product updates
ProAmpac launches enhanced online pouch configurator MAKR by DASL for custom flexible packaging prototypes
Smart Packaging Tech
Yesterday
Funding
M&A
Majority stake in Bollegraaf Group acquired by Summa Equity for EUR 800 million
Waste Recovery & Management Tech
Yesterday
Partnerships
NASA awards Intuitive Machines contract for near-space network services
Space Travel and Exploration Tech
Yesterday
Partnerships
FinFit partners with Sunny Day Fund to offer emergency savings accounts
Financial Wellness Tools
Yesterday
Partnerships
KSP partners with Peak Technologies and Locus Robotics for warehouse automation
Logistics Tech
Yesterday
Preventive Healthcare

Preventive Healthcare

Sep 2, 2024

iRhythm wearable heart monitor increases AFib diagnoses by 52%

Product updates

  • Zio XT, a wearable heart monitor developed by digital healthcare company iRhythm was tested in the GUARD-AF study. The study results showed that the Zio XT increased atrial fibrillation (AFib) diagnoses by 52% compared to standard care, with diagnosis rates of 5.0% vs. 3.3% over an average 15-month follow-up period.

  • The study involved nearly 12,000 patients aged 70 or above across the US and aimed to compare the device's effectiveness in detecting AFib against regular care. The Zio XT is a lighter, more discreet alternative to traditional Holter monitoring, allowing patients to wear the device for two weeks, enabling longer-term electrocardiogram monitoring.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.